Boston
Therapeutics, an innovator of drugs that target diabetes using complex
carbohydrate chemistry, today announced the appointment of three management
positions within its ranks. Effective immediately, Edward Shea will serve as
Vice President Business Development, Tina M. Gagnon will serve as Consulting
Director of Finance, and Yael T. Bobruff, Ph.D. will serve as Clinical Affairs
Manager, respectively.
David
Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, said, “As Boston
Therapeutics enters the next phase of its growth, it is imperative that we
attract top talent to help us advance and commercialize our drug development
programs. Ed Shea and Tina Gagnon’s business and finance backgrounds, and Dr.
Bobruff’s expertise in biology and research significantly strengthen our
management team. I am pleased they have decided to join our company, and I look
forward to working with them in the months and years ahead.”
Mr.
Shea boasts of 25 years of experience in commercial development, marketing, and
sales. Of that, 15 years of his experience includes business development,
marketing, and sales leadership positions with GlaxoSmithKline and Salix
Pharmaceuticals, as well as business development capacities with two startup
biopharmaceutical companies, ViroPharma and Critical Therapeutics. Mr. Shea
most recently worked with ViroPharma, Inc. as Sr. Eastern Area Sales Director.
He holds a B.S. in Business/Marketing and an M.B.A. from Salve Regina
University in Newport, RI.
Ms.
Gagnon brings over 20 years of experience in finance. Most recently, she worked
as Corporate Controller at Micronetics, Inc., at which she oversaw a staff
responsible for accounts receivable, accounts payable, inventory management,
and other activities. Beforehand, she served in the following capacities:
Controller at Amherst Technologies, LLC; Assistant Controller of Fruit of the
Loom’s Sports & Licensing Division; and Senior Corporate Auditor at Standex
International Corp. Ms. Gagnon holds a B.S. in Accountancy from Bentley
College.
Most
recently, Dr. Bobruff was a postdoctoral researcher in the Department of
Systems Biology at Harvard University Medical School in Boston. There, she investigated
in depth the genetic processes and mechanisms contributing to the evolution of
host-pathogen interactions. Dr. Bobruff holds a B.Sc. in Biology from the
Hebrew University of Jerusalem, a M.Sc. in Civil and Environmental Engineering,
and a Ph.D. in Biological Science from Stanford University.
For
more information, visit www.bostonti.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
